Myeloproliferative diseases.
The various myeloproliferative diseases have different symptoms, therapeutic problems, and prognoses. The most common of these disorders appears to be agnogenic myeloid metaplasia, which primarily affects older persons. The five-year survival rate at the Mayo Clinic for these patients is 58%, and the prognosis depends on the presence of symptoms, anemia, and thrombocytopenia and on the size of the liver. Androgen therapy is often necessary to control anemia, and splenectomy may be indicated.
D000328:Adult; D000368:Aged; D002699:Chlorambucil / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000628:therapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000188:drug therapy / Q000628:therapy; D055728:Primary Myelofibrosis / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D013920:Thrombocythemia, Essential / Q000188:drug therapy
D010761:Phosphorus Radioisotopes; D002699:Chlorambucil; D008558:Melphalan